TABLE 1. Characteristics of anxiety-related adverse events after receipt of Janssen COVID-19 vaccine (N = 64) — five U.S. mass vaccination sites, April 7–9, 2021.
| Characteristic | Vaccination site, no. (%) |
||||
|---|---|---|---|---|---|
| A | B | C* | D | E | |
| Event date |
Apr 7–9 |
Apr 8 |
Apr 7 |
Apr 7 |
Apr 7 |
| First Janssen vaccination event |
Y |
Y |
Y |
Y |
N |
| Drive-through site |
Y |
Y |
N |
Y |
Y |
| No. vaccinated, total (per day) |
3,901 (881; 1,673; 1,347) |
2,323 |
37 |
593 |
1,770 |
| No. of cases,† total (per day) |
29 (10; 12; 7) |
12 |
4 |
8 |
11 |
| Cases per 1,000 vaccinated, total (per day) |
7.4 (11.4; 7.2; 5.2) |
5.2 |
10.8 |
13.5 |
6.2 |
| Vaccination temporarily suspended |
N |
Y |
Y |
Y |
Y |
|
Case characteristic, no. (%)
| |||||
| Women |
18 (62) |
6 (50) |
4 (100) |
4 (50) |
7 (64) |
| Age range, yrs (median) |
23–77 (42) |
21–63 (40) |
19–33 (20) |
25–62 (34) |
18–59 (35) |
| Transported to emergency department§ |
6 (21) |
3 (25) |
1 (25) |
1 (13) |
2 (18) |
| Reported history of anxiety related to needles or medical visits |
7 (24) |
4 (33) |
1 (25) |
0 (0) |
1 (9) |
|
Common signs and symptoms
| |||||
| Chest pain |
3 (10) |
0 (0) |
1 (25) |
0 (0) |
0 (0) |
| Hypotension |
3 (10) |
3 (25) |
0 (0) |
2 (25) |
2 (18) |
| Light-headedness or dizziness |
19 (66) |
4 (33) |
3 (75) |
3 (38) |
7 (64) |
| Nausea/Vomiting |
10 (34) |
2 (17) |
0 (0) |
1 (13) |
3 (27) |
| Pallor or diaphoresis |
7 (24) |
2 (17) |
1 (25) |
6 (75) |
4 (36) |
| Seizure-like activity |
0 (0) |
0 (0) |
1 (25) |
3 (38) |
1 (9) |
| Syncope |
5 (17) |
4 (33) |
2 (50) |
3 (38) |
3 (27) |
| Tachycardia | 2 (7) | 1 (8) | 1 (25) | 0 (0) | 0 (0) |
Abbreviations: N = no; Y = yes.
* Site C was located on a college campus that was vaccinating students.
† An anxiety-related adverse event was defined as any of the following occurring in a person during the 15-minute postvaccination observation period at one of the five sites reporting these events: tachycardia, hyperventilation, dyspnea, chest pain, paresthesia, light-headedness, hypotension, headache, pallor, or syncope. Persons with allergic-like symptoms and those who received diphenhydramine or epinephrine were excluded.
§ Thirteen patients were transported to an emergency department for further medical evaluation; all five patients with available follow-up information were released later that day.